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Abstract 
Chemokine-GAG interactions are crucial to facilitate chemokine immobilization, resulting in the 
formation of chemokine gradients that guide cell migration. Here we demonstrate 
chromatographic isolation and purification of two heparin hexasaccharide isomers that interact 
with the oligomeric chemokine MCP-1/CCL2 with different binding affinities. The sequences of 
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these two hexasaccharides were deduced from unique MS/MS product ions and HPLC 
compositional analysis. IM-MS (Ion mobility mass spectrometry) showed that the two isolated 
oligosaccharides have different conformations and both displayed preferential binding for one of 
the two distinct conformations known for MCP-1 dimers. A significant shift in arrival time 
distribution of close to 70 Å
2
 was observed, indicating a more compact protein:hexasaccharide 
conformation. Clear differences in the MS spectra between bound and unbound protein allowed 
calculation of Kd values from the resulting data. The structural difference between the two 
hexasaccharides was defined as the differential location of a single sulfate at either C-6 of 
glucosamine or C-2 of uronic acid in the reducing disaccharide, resulting in a 200 fold difference 
in binding affinity for MCP-1. These data indicate sequence specificity for high affinity binding, 
supporting the view that sulfate position and not simply the number of sulfates, is important for 
HS-protein binding. 
 
Introduction 
Heparin and heparan sulfate (HS) are part of the GAG family of linear polysaccharides, 
composed of a repeating disaccharide building block of a uronic acid (glucuronic acid or its 
epimer, iduronic acid, which can be sulfated at the carbon 2 position), and glucosamine (which 
can be O-sulfated on the carbon 6 and rarely, carbon 3 position, while the N-group can contain 
either a sulfate, an acetate, or a free amine)5. Variability in the extent and patterns of sulfation 
gives rise to a high diversity of structures and functions6.  
Highly basic patches on chemokine proteins make them likely binding partners both in 
vitro and in vivo7-9, and chemokine–GAG interactions are thought to facilitate chemokine 
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immobilization, resulting in the formation of a directed chemokine gradient to guide cell 
migration and prevent dissociation under the shear forces of blood flow1, 7, 10. Under these 
conditions, the GAGs provide an anchor, protection against proteolysis, and a site-specific 
concentration gradient11-13. Mutagenesis of putative GAG-binding sites on chemokines shows the 
functional relevance of this interaction14-15.  
Chemokine oligomerization is thought to be a hallmark of chemokine function, with very 
few chemokines functioning as monomers in vivo. The formation of chemokine oligomers has 
also been strongly associated with chemokine–GAG interactions16-19. For MCP-1/CCL2 GAG 
binds to both dimer and tetramer states14, 20-21. Mutations in the key binding residues (Arg18, 
Lys19, Arg24, and Lys49) causes decreased ability to bind heparin and form complexes. 
Interestingly, the mutation P8A-CCL2 prevents oligomerization, and although heparin was still 
able to bind in vitro, in vivo leukocyte adhesion and migration were not observed14, 22-23. This 
was unexpected as GAG binding results in oligomerization and both are a requirement for in vivo 
receptor activation and it would be expected that both processes would be affected in vivo14, 22-23. 
Interestingly, chemokines with this mutation are linked with a significant reduction in adjuvant-
induced arthritis22-23. While most studies have focused on the mutation of the MCP-1/CCL2 
protein, structural changes in HS during disease progression may also play a role24. Indeed, it has 
been observed that HS structures change depending on the severity of rheumatoid arthritis24. 
Other protein–GAG disease progression models have also shown structural changes to the GAG 
chain25-26. Nevertheless, sequence-specific interactions have only been identified in a handful of 
cases; for MCP-1/CCL2 O-sulfation is possibly more relevant than N-sulfation27 and there is a 
preference towards highly sulfated regions28-30.  
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Interestingly, MCP-1 is predominantly upregulated in rheumatoid arthritis31, resulting in 
upregulation of cytokines and an inflammatory response that causes the enzymatic digestion of 
connective tissues. Small anionic molecules, nucleotides and peptides have shown promise for 
inhibiting protein-GAG oligomerization32-35, but it is logical to use GAGs36 as these molecules 
are known regulators of MCP-1 activation and inhibition14, 34, 37-39. However, due to the 
complexity observed within GAGs, the isolation of single saccharide species is challenging. 
Separation methods for heparin and HS oligosaccharides have improved over the last 10 years, 
with new chromatography methods using graphite40-41, hydrophilic interaction chromatography 
(HILIC)42 and cetyltrimethylammonium strong anion exchange (CTA-SAX)43. Recently we 
described a novel CTA-SAX method using volatile salts (Miller et al, submitted to Analytical 
Chemistry) which together with other established HPLC techniques now offers enhanced 
capabilities for high purity separations of heparin / HS oligosaccharides. We rationalized that it 
might now be possible to purify smaller MCP-1 binding saccharides, since this would be 
preferable to gain greater target specificity and fewer undesirable side effects, as shown with the 
anticoagulant pentasaccharide drug, Arixtra44. 	  
Herein, we used tandem SAX separations and affinity chromatography in combination 
with ion mobility and tandem MS to show that MCP-1 does show a preference towards highly 
sulfated regions, although a high amount of negative charge alone was insufficient for increased 
binding affinity. Two highly sulfated isomeric structures displayed drastically different affinities 
towards MCP-1. This indicates that sequence and conformation of the GAG are both important 
for binding, and that the isolation of purified isometric structures is required to properly elucidate 
protein-GAG interactions and their functional consequences. 
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Experimental methods 
Materials and reagents 
All chemical and biochemical products were of analytical grade and purchased from 
VWR (Lutterworth, UK) and Sigma (Gillingham, UK) unless otherwise indicated. Disaccharide 
standards 1–8 were purchased from V-Laboratories (Covington, LA) except for standard 3, 
which was obtained from Iduron (Manchester, UK). Heparin was purchased from Alfa Aesar 
(Massachusetts, USA). All materials were digested with recombinant heparinase enzymes I, II 
and III obtained from IBEX (Canada).  
Digestion of heparin 
Heparin (1 g) was reconstituted in 500 µL of lyase buffer (100 mM sodium acetate, 10 
mM calcium acetate). Enzyme reactions were performed using 1 mU of heparinase I to 10 mg of 
heparin and were incubated at 37 °C. The reaction was stopped at set time points; 2, 3, 4, 6 and 8 
hours by removing a 120 µL aliquot and denaturing heparinase I at 98 oC for 3 minutes. All 
aliquots were pooled and the resulting products were further separated as described below. 
Size exclusion chromatography (SEC) 
SEC separations were performed on a Waters Delta 600 HPLC system (Waters Corp., 
Milford, MA, USA) using a Biorad Econo column packed in-house with preparation grade 
Superdex 30 beads (15 mm × 170 cm, bead size 34 µm – GE Healthcare). A 500 mg sample of 
pooled digested heparin was made up to a total of 1 mL, injected and separated using an eluent 
of 0.5 M ammonium bicarbonate at a flow rate of 0.1 mL / minute. The elution profile was 
monitored with an absorbance at 232 nm. Fractions containing heparin oligosaccharides were 
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pooled and repeatedly freeze-dried using HPLC grade water until all the ammonium bicarbonate 
was removed.  
C18-strong anion exchange chromatography (SAX) 
MCP-1 (25 nM) and a heparin dp6 (25 nM) SEC fraction were incubated for 30 minutes 
in a 0.1 M NaCl solution with a total volume of 50 µL. This reaction was then loaded at 10 µL / 
minute onto a C18 trap BDS silica column (15 mm × 2.1 mm, 5 µm bead size – Sigma). The 
flow-through was cycled around the C18 column three times to ensure complete loading45. 
Equilibration of the column was completed using a Delta 600 HPLC (Waters) in eluent A for 20 
minutes at 0.2 mL / minute to ensure that all the unbound oligosaccharide had been eluted from 
the column. The C18 trap column was coupled with a Propac PA1 column (4.6 mm × 250 mm, 5 
µm bead size – Dionex) and equilibrated in eluent A for 20 minutes at 0.2 mL / minute. C18-
SAX separations were performed using a Delta 600 HPLC (Waters), with a UV-visible 
spectrophotometric detector. The elution profiles were monitored with an absorbance at 232 nm. 
A linear gradient of 0.1 M–1.4 M NaCl was generated appropriately by mixing eluents A and B 
over 90 minutes, using a flow rate of 0.2 mL / minute for the elution, at a temperature of 40 °C. 
Appropriate fractions were desalted in HPLC grade water using a Hitrap desalting column (GE 
Healthcare) on an isocratic path. 
Strong anion-exchange chromatography (SAX) 
Separation of SEC fractions were performed on a Waters Delta 600 HPLC system 
(Waters Corp., Milford, MA, USA) using a SAX Propac PA1 column (4.6 mm × 250 mm, 5 µm 
bead size – Dionex). Eluent A was HPLC-grade water and eluent B was 2 M NaCl. A dp6 SEC 
fraction was injected and loaded on to the column, and a gradient of 0 M–1.4 M NaCl was 
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generated appropriately by mixing eluents A and B over  
90 minutes using a flow rate of 1 mL / minute for the elution, at a temperature of 40 °C. 
Subsequent shallower SAX gradients were generated using the same instrument, column and 
eluents, with the gradient being changed to 0.84 M–1.2 M NaCl over 60 minutes.  
VSCTA-SAX chromatography  
VSCTA-SAX separations were performed on a Delta 600 HPLC (Waters) using a 
cetyltrimethylammonium derivatized C18 column (4.6 mm × 250 mm, 5 µm bead size – Sigma) 
(Miller et al, submitted to Analytical Chemistry). The C18 column was derivatized with 1 mM 
cetyltrimethylammonium in water: methanol ratio of 40 : 60 (v/v). Eluent A was HPLC grade 
water and eluent B was 2 M ammonium bicarbonate. The elution profiles were monitored with 
an absorbance at 232 nm. Oligosaccharides collected from the Propac PA1 column were diluted 
1 in 10 in water and multiple injections were performed to load the sample onto the VSCTA-
SAX column. VSCTA-SAX was used to separate peak C further on a 0.8 M – 1.5 M ammonium 
bicarbonate gradient over 60 minutes using a flow rate of 1 mL / minute, at a temperature of 40 
°C. Each fraction was dried on a SPD121B speed vac (Thermo Scientific) prior to mass 
spectrometry and compositional analysis. 
Compositional analysis 
Oligosaccharides collected from the VSCTA-SAX column were digested using 10 µL of 
1 mU / 1µL, heparinase I, heparinase II and heparinase III to create disaccharides46,47-48,49. The 
reaction was incubated at 30 oC for 24 hours so that complete digestion could be achieved. Both 
hexasaccharide structures were digested to disaccharides and separated using a Propac PA1 
column on a 0-1 M NaCl gradient over 60 minutes. Disaccharide standards were injected onto 
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the same column and separated under the same conditions so that the disaccharide standards and 
the hexasaccharide samples could be compared. Elution profiles were monitored with an 
absorbance of 232 nm.  
IM-MS of isomeric hexasaccharides 
IMMS was performed on two purified hexasaccharides using a Synapt G1 mass 
spectrometer equipped with a T-wave mobility cell (Waters). The Synapt G1 instrument was 
calibrated in negative ion mode using sodium iodide as a standard. The concentration of each 
hexasaccharide was calculated based on its absorbance at 232 nm. An 0.5 µM hexasaccharide 
concentration in water / acetronitrile (50/50 v/v) with 500 mM ammonium hydroxide was loaded 
into borosilicate electrospray tips made in-house as previously described50. Each hexasaccharide 
was infused into the mass spectrometer and ionized in negative ion mode using a capillary 
voltage of 0.55 kV, a sample cone voltage of 7 V and an extraction cone voltage of 0.6 V. The 
ion mobility parameters were optimized and conditions were identical for each hexasaccharide 
sample, and all parameters can be found in supplementary materials. MS/MS was performed on 
m/z of 549.3 [M-3H]3− and collisional activated at 15 V in the transfer cell with the ion mobility 
cell turned off in order to produce comparable CID (Collision induced dissociation) data for each 
isomer.  
Ion mobility of MCP-1: hexasaccharide complexes 
IM-MS of MCP-1: hexasaccharide complex was performed on a Synapt G2 mass 
spectrometer equipped with a T-wave mobility cell. The hexasaccharide concentrations were 
calculated based on its 232 nm absorbance and the MCP-1 concentration was based on the 
expressed, isolated and purified MCP-1 previously described51. The borosilicate tips were made 
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in house as stated in previous publications50. The Synapt G2 instrument was calibrated with 
cesium iodide (50 µg / µL) over a mass range of 500 – 8,000. IM-MS data were calibrated as 
previously described52 using the drift times of the 11+ through 21+ charge states of 10 µM horse 
heart myoglobin in 50 % acetonitrile, 0.1 % formic acid. Data were analysed using Mass Lynx 
4.1. MCP-1 was sprayed at a concentration of 10 µM, whereas the hexasaccharides were 
incubated with MCP-1 at concentrations of 40 µM, 20 µM, 10 µM, 5 µM, and 2.5 µM. Each 
MCP-1: hexasaccharide sample was sprayed in a borosilcate gold coated tip and each mass 
spectra were acquired in positive mode with a capillary voltage of 0.78 kV and a sample cone 
voltage of 17 V. The ion mobility parameters that the instruments were operated in were; trap 
collision energy, 3 V; transfer collision energy, 0 V; trap DC bias, 40 V; trap gas flow, 4 mL / 
minute (Ar); IM-MS gas flow, 90 mL / minute (N2). The backing pressure on the Synapt G2 was 
optimised to preserve the MCP-1: hexasaccharide complex and was set to 6.5 mBar by 
regulating the backing scroll pump with a speedi valve. IM-MS wave velocity was set to 725 m/s 
and the IM-MS wave height was set to 40 V. A 32 kV radio frequency generator was used to 
supply voltage to the quadrupole. LM resolution was set to 4.7 and HM resolution was set to 15.  
Results and Discussion 
C18 affinity enrichment method for MCP-1: oligosaccharide interactors 
Heparin oligosaccharides were digested by heparinase I and separated using SEC 
chromatography (Supporting Information, Figure S-1) to obtain size defined fractions. Each 
fraction was collected and then analyzed using mass spectrometry to determine the dominant size 
of oligosaccharides within each SEC peak (data not shown). A dp6 (hexasaccharide) mixture was 
chosen, as this is likely to contain both MCP-1 activators and inhibitors with strong specificity. 
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Hexasaccharides that bind to MCP-1 were then isolated using a two dimensional C18-
SAX affinity method (Figure 1). The hexasaccharide mixture was first passed through the two 
dimensional column in the absence of MCP-1 to identify the elution positions of all 
hexasaccharides in the mixture (Figure 1a). MCP-1 was then incubated with the hexasaccharide 
mixture before the MCP-1-hexasaccharide complexes were bound to the C18 column. 
Hexasaccharides that formed MCP-1 complexes and which were amenable to dissociation with 
salt, were captured and resolved using a Propac SAX column (Figure 1b). Peak A was present in 
trace (a) but reduced in trace (b), indicating that both MCP-1 binding and nonbinding 
saccharides were present in the peak. As peak A elutes at higher salt concentrations, it is likely to 
have a higher number of sulfate groups and thus it was chosen, as a candidate, to probe the 
various isomeric structures and their affinities for MCP-1.   
Other affinity methods have been used to identify differential binding to heparin / HS, 
including biotinylated proteins53, so we also performed this enrichment method as a comparison. 
The major drawback to this method is that biotinylated MCP-1 binds to streptavidin in a 
monomeric state, not the naturally occurring dimer (Figure S-2). The streptavidin bound MCP-1: 
hexasaccharide complex only retained the final oligosaccharide peak, unlike the C18 bound 
MCP-1: hexasaccharide complex. Protein: oligosaccharide assembly dynamics are the likely 
reason for this result. Subunit packing and conformational changes are critical for biological 
affinity, and these would be more naturally observed with the C18-SAX method. 	  
Preparative scale purification of MCP-1 binders and non-binders 
To further purify isomeric hexasaccharides from Peak A and obtain sufficient material for 
characterization, preparative scale dp6 oligosaccharide separation (Figure S-1) and C18-SAX 
oligosaccharide separation were repeated under the same conditions as shown in Figure 1. Peak 
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A was identified in the preparative oligosaccharide SAX separation based on elution position and 
was further purified (Figure 2a). Peak A was separated using a shallower SAX gradient (Figure 
2b), resulting in the separation of two subsequent peaks, peak B and peak C (Figure 2b). Peak C 
was separated by VSCTA-SAX chromatography into two further peaks (Figure 2c), peak D and 
peak E. Although baseline resolution was not observed between peaks D and E, both were 
successfully collected and shown to be pure compounds. The lack of baseline resolution is not 
uncommon in the separation of heparin oligosaccharides49, 54, thus the partial collection of each 
peak is required to isolate pure structures.  
Ion mobility and sequencing of two isomeric structures  
To confirm that peak D and peak E were indeed different structures, IM-MS was 
performed on both (Figure 3a). Arrival time distributions (ATD) of peak D exhibited a more 
compact structural conformation with an ATD of 3.46 ms, whereas peak E exhibited a more 
extended conformation with an ATD of 3.60 ms (Figure 3a). MS of compounds D and E showed 
that both structures had the same molecular ion at m/z of 549.3 [M-3H]3- (data not shown). 
Oligosaccharides with this m/z correspond to a dp6 + 8SO3. Tandem mass spectrometry of 
hexasaccharide D and hexasaccharide E resulted in different product ion spectra (Figure 3b, 
Figure S-3 and Figure S-4), which is not unusual for MS/MS of GAG isomers55. As expected, 
the product ions for both spectra showed sulfation losses and a doubly-charged product ion at 
m/z of 576, corresponding to dp4 + 6SO3. As dp4 + 6SO3 is fully sulfated, both hexasaccharide 
D and E contain two repeating tri-sulfated disaccharides, but differ in the sulfation of the third 
disaccharide unit (Figure S-3 and S-4). Compositional analysis47 confirmed that both 
hexasaccharides contained ∆UA2S - GlcNS6S, while hexasaccharide D contained ∆UA - 
GlcNS6S and hexasaccharide E contained a ∆UA2S - GlcNS (Figure 3c). This leaves the 
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possibility of two structural sequences for hexasaccharide D ∆UA2S - GlcNS6S - UA2S - 
GlcNS6S - UA - GlcNS6S and ∆UA - GlcNS6S - UA2S - GlcNS6S – UA2S - GlcNS6S and for 
hexasaccharide E ∆UA2S - GlcNS6S - UA2S - GlcNS6S - UA2S – GlcNS and ∆UA2S - GlcNS 
- UA2S - GlcNS6S - UA2S – GlcNS6S. Analysis of the B, Y, C and Z ions allowed 
determination of the sequence from unique cross ring cleavages (Figure S-3 and S-4).  MS/MS 
confirmed that the structure of hexasaccharide D is ∆UA2S - GlcNS6S - UA2S - GlcNS6S - UA 
- GlcNS6S, and the structure of hexasaccharide E is ∆UA2S - GlcNS6S - UA2S - GlcNS6S - 
UA2S - GlcNS. 
MCP-1: hexasaccharide interactions 
Under IM-MS conditions, MCP-1 exists in two conformations as a homodimer. One is 
the α conformation, which is more compact while the other is the β conformation, which exhibits 
a more extended conformation resulting from the flexible N-terminal region within MCP-120. As 
a control, MCP-1 (in the absence of any hexasaccharide) was sprayed under native conditions 
and the MCP-1 dimer at m/z, 2171 was extracted from the IM-MS chromatogram.  ATD for the 
two conformations are shown in Figure 4a. To ensure that no other MCP-1 assembly was present 
at the same m/z as the MCP-1 dimer: hexasaccharide complex (which would appear at m/z 
2377), this ion was also extracted from the IM-MS chromatogram (Figure 4b). Figure 4b clearly 
shows an absence of any conflicting or overlapping ATD at the m/z of 2377.    
To further identify binding of the purified hexasaccharides, IM-MS was performed on 
MCP-1 dimer complexes with hexasaccharides D and E, respectively (Figures 4c - 4f). 
Incubation of hexasaccharide D with MCP-1 (Figure 4c and 4d) produced the same α and β 
conformations of the MCP-1 dimer but the ATD showed very different relative intensities for the 
two conformers, with the β form being only 29% of the level of the α form (Table S-1). Data in 
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Figure 4d indicates that hexasaccharide D preferred to complex with only one conformation of 
the MCP-1 dimer (β) as evidenced by the single peak in Figure 4d and the clear depletion in 
abundance of the β conformation in Figure 4c and Table S-1. The MCP-1 dimer: hexasaccharide 
D complex resulted in a collisional cross section (CCS) (1804 Å
2
) indicative of further folding to 
a more compact structure compared to the unbound beta MCP-1 dimer with a CCS of 1875 Å
2
. 
ATD shown in Figures 4e and 4f also indicated a preference for the β - conformer complex upon 
binding of hexasaccharide E, albeit to a much less degree than hexasaccharide D (Table S-1). 
This may be due to the flexible N-terminal regions that bridge across the protein upon 
oligosaccharide binding20, as it is known that this region of MCP-1 induces oligomerization with 
GAG binding and anchoring of the N-terminal region into a more fixed position14, 21, 56. Site 
directed mutations of single, double and triple knockouts of positivity charged residues validated 
this heparin interaction56. A mutation in the N-terminal region P8A-MCP-1 prevented 
oligomerization upon interaction with heparin and affected MCP-1 ability to induce in vivo 
leukocyte adhesion and migration22-23. The flexible N-terminal region is required for 
oligomerization and previous data showed that MCP-1: GAG interaction caused a 
conformational change; thus it would be expected that the same conformation change is being 
observed in the ATD upon MCP-1: GAG binding of hexasaccharide D and E. 
To better address the observed differences between the two conformations, the Kd for 
each interaction was calculated using the following equation: 
 
Kd = [free MCP-1][free hexasaccharide] / [bound MCP-1 hexasaccharide complex] 
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Since the intensities of free protein, free hexasaccharide and bound protein–hexasaccharide are 
known from the MS spectra (Figure S-5), it is possible to calculate a Kd value by altering only 
the hexasaccharide concentration17. The Kd value calculated from MS spectra of the MCP-1 
dimer: hexasaccharide D complex displayed strong association kinetics (Figure 5 and Figure S-
5), and resulted in a relatively strong value of 1.12 µM. A Kd value for hexasaccharide E cannot 
be ascertained with certainty due to the weak interaction with MCP-1, showing a quadratic curve 
as linear, resulting in a large error associated with this value. What can be shown from the data is 
that hexasaccharide E is a relatively weak binder of MCP-1 compared to hexasaccharide D 
(Figure 5). It is unlikely that hexasaccharide E would have been retained in the affinity 
enrichment method as competitive stoichiometry would have bound a higher affinity structure.  
Crystallography has identified MCP-1 as existing in both dimer and tetramer complexes upon 
GAG interaction20, 57; however, although tetrameric complexes are believed to exist, biological 
evidence to date only supports MCP-1 dimerization. ATD of the tetramer complex isolated from 
the IM-MS chromatogram is shown in Figure S-6. MCP-1 in the absence of a hexasaccharide 
(Figure S-6a and b), showed that MCP-1 had a CCS of 2041 Å
2
. The MCP-1 tetrameric complex 
with and without hexasaccharide D (Figure S-6c and d) showed no change in the ATD, whereas 
the ratio of free tetrameric MCP-1 to hexasaccharide D bound tetrameric MCP-1 was ~ 4-fold 
larger. MCP-1 tetrameric complex with and without hexasaccharide E (Figure S-6e and f) again 
showed no change in the ATD, whereas the ratio of free tetrameric MCP-1 to hexasaccharide D 
bound tetrameric MCP-1 was decreased ~5-fold. 
 
Conclusions 
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In this study we used a C18-SAX affinity methodology to identify specific isomeric 
oligosaccharides that bind differentially to MCP-1.  
Both hexasaccharides D and E meet the known binding requirements for MCP-1 (i.e. 
they are highly sulfated with eight negative charges), however, one structure bound with high 
affinity and the other with significantly lower affinity. The sulfation difference between the two 
structures is the position of a sulfate on C-6 of glucosamine and a sulfate on C-2 of the uronic 
acid. Knowing that MCP-1 prefers highly sulfated structures, it is possible that the sulfate on C-2 
might inhibit, and/or the sulfate on the C-6 might promote stronger interactions with MCP-1. 
This is further complicated by changes in the hexasaccharide conformation due to the position of 
the O-sulfate, making the molecule physically unfavorable to fit in the protein binding pocket.  
Regardless of the exact mechanism, our data does indicate that MCP-1 has significant 
sequence specificity for heparin/HS, with the sulfate position, not just the number of sulfates, is 
critical for high affinity binding. Here we demonstrated an approach for purification and 
identification of specific isomeric structures with different protein binding properties. For MCP-
1 we anticipate that this will allow further isolation and purification of specific oligosaccharides 
that may show different biological activities towards the protein and possibly afford development 
of new treatments for inflammatory diseases.  
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Figure 1. MCP-1: hexasaccharide enrichment using a C18-SAX method. MCP-1 was 
incubated with a heparin hexasaccharide mixture, resulting in natural oligomerization. MCP-1 
complexes were bound to the C18 column and unbound oligosaccharides were removed from the 
C18 trap before coupling to a SAX column to improve resolution. MCP-1 dissociated 
hexasaccharides were then eluted with a gradient of 0.1 M - 1.4 M NaCl over 90 minutes. a) The 
hexasaccharide mixture in the absence of MCP-1 b) The hexasaccharide mixture in the presence 
of MCP-1. 
Figure 2. Preparative scale hexasaccharide purifications of MCP-1 binders and non-
binders. a) Preparative SAX separation of the same hexasaccharide mixture used in the affinity 
enrichment methodology. Peak A was observed to retain compounds that had a preference to be 
both binders of MCP-1 and non-binders of MCP-1. b) Peak A was separated further on a more 
shallow 0.84 M – 1.2 M NaCl SAX gradient over 60 minutes, isolating peak B and peak C. c) 
VSCTA-SAX was used to separate peak C further on a 0.8 M – 1.5 M ammonium bicarbonate 
gradient over 60 minutes, isolating peak D and peak E. 
Figure 3. Sequencing of two isomeric hexasaccharides that exhibited differences in 
structural conformation a) Ion mobility separation of peak D showed a more compact 
structural conformation with an ATD of 3.46 ms, whereas ion mobility separation of peak E 
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showed a more extended structural conformation with an ATD of 3.60 ms. MS showed that both 
structures had the same m/z of 549.3 [M-3H]3−, which corresponds to a dp6 + 8SO3 b) MS/MS 
of two dp6 + 8SO3 structures (peak D and peak E). c) Compositional analysis of peak D and 
peak E. Standards 1 to 5 correspond to 1 - ∆UA2S - GlcNAc, 2 - ∆UA - GlcNS6S, 3 - ∆UA2S - 
GlcNS, 4 - ∆UA2S - GlcNAc6S, 5 - ∆UA2S - GlcNS6S  
Figure 4. IMMS ATD of MCP-1: hexasaccharide complexes. a) and b) IM-MS of MCP-1 
dimer, c) and d) MCP-1 complexed with the hexasaccharide isolated from peak D, e) and f) 
MCP-1 complexed with the hexasaccharide isolated from peak E. ATD of ions extracted at m/z 
2171 (no saccharide bound) and m/z 2377 (hexasaccharide D or E bound to MCP-1 dimer).  See 
texts for full details.  
Figure 5. Calculated Kd for two isomeric hexasaccharides in complex with the MCP-1 
dimer. a) Calculated Kd of hexasaccharide D complexed with the MCP-1 dimer. b) Calculated 
Kd of hexasacharide E complexed with the MCP-1 dimer. 
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Figure 1. MCP-1: hexasaccharide enrichment using a C18-SAX method.  
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Figure 2. Preparative scale hexasaccharide purifications of MCP-1 binders and non-
binders.  
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Figure 3. Sequencing of two isomeric hexasaccharides that exhibited differences in 
structural conformation  
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Figure 4. IMMS arrival time distributions (ATD) of MCP-1: hexasaccharide complexes. 
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Kd	  Value	   Std	  Error	  
Hexasaccharide	  D	   1.1	  µM	   0.5	  
Hexasaccharide	  E	   215.8	  µM	   148.2	  
 
Figure 5. Calculated Kd for two isomeric hexasaccharides in complex with the MCP-1 
dimer.  
 
